International: +1-347-960-6455
Pontine Glioma Therapeutics - Pipeline Analysis 2018

Pontine Glioma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10117 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Oncology
Select License Type
$2200
$2600
$3950

Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour. The only efficient treatment for pontine glioma is radiotherapy; as surgery is not possible due to the tumor’s position in the brain stem. Company like Y-mAbs Therapeutics Inc. is in the process of developing omburtamab for the treatment of pontine glioma.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.